CBT vs CC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cabot Corporation presents a stable but stagnating profile, evidenced by a Piotroski F-Score of 4/9. While the company maintains strong profitability with an ROE of 21.82% and a consistent track record of earnings beats, it is currently facing significant headwinds with negative YoY revenue (-11.10%) and earnings growth (-18.20%). The stock is trading at a significant premium to both its Graham Number ($62.31) and Intrinsic Value ($40.04), suggesting limited upside potential at current price levels.
The Chemours Company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 17.51. While the stock has seen a massive 1-year price surge of 119.6%, this momentum is decoupled from fundamentals, as evidenced by a negative ROE of -93.80% and shrinking revenue. The dividend is unsustainable with a payout ratio of 555.56%, and the current price of $26.61 already exceeds the analyst target price of $21.67. Overall, the company appears to be in a high-risk state with significant solvency concerns.
Compare Another Pair
Related Comparisons
CBT vs CC: Head-to-Head Comparison
This page compares Cabot Corporation (CBT) and The Chemours Company (CC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.